A phase 1 trial tested the experimental obesity medication to evaluate the pharmacokinetics and safety of immediate- and modified-release formulations of danuglipron. The study enrolled healthy adults and assessed four formulations, according to clinicaltrials.gov.
“To date, study results have demonstrated a pharmacokinetic profile supportive of once-daily dosing with a safety profile consistent with prior danuglipron studies including no liver enzyme elevations observed in more than 1,400 study participants,” Pfizer said in a news release.
The drugmaker said it will conduct dose optimization studies in the second half of 2024.
The FDA has approved 10 GLP-1 receptor agonist medications, which treat diabetes, weight loss and serious heart conditions. Currently, the only approved oral formulation is Novo Nordisk’s Rybelsus (semaglutide), which is indicated for Type 2 diabetes.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
